Expediting treatments in the 21st century: orphan drugs and accelerated approvals
Background In response to activated patient communities’ catalyzation, two significant efforts by the FDA to expedite treatments have now been in place for multiple decades. In 1983, the United States Congress passed the Orphan Drug Act to provide financial incentives for development of drugs for ra...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
BioMed Central
2024
|
| Online Access: | https://hdl.handle.net/1721.1/157535 |
| _version_ | 1824458006199271424 |
|---|---|
| author | Domike, Reuben Raju, G. K. Sullivan, Jamie Kennedy, Annie |
| author2 | Massachusetts Institute of Technology. Center for Biomedical Innovation |
| author_facet | Massachusetts Institute of Technology. Center for Biomedical Innovation Domike, Reuben Raju, G. K. Sullivan, Jamie Kennedy, Annie |
| author_sort | Domike, Reuben |
| collection | MIT |
| description | Background In response to activated patient communities’ catalyzation, two significant efforts by the FDA to expedite treatments have now been in place for multiple decades. In 1983, the United States Congress passed the Orphan Drug Act to provide financial incentives for development of drugs for rare diseases. In 1992, partly in response to the HIV epidemic, the FDA implemented Accelerated Approval (AA) to expedite access to promising new therapies to treat serious conditions with unmet medical need based on surrogate marker efficacy while additional clinical data is confirmed. The uses of these regulatory approaches over time are assessed in this study. Methods The following U.S. FDA CDER published lists were used in this analysis: 1. all orphan designations and approvals; 2. all AA and their details updated through December 31, 2022; new molecular entities (NMEs). Results Orphan drug designations and approvals have increased several-fold over the past four decades. The largest increase recently has been in therapies targeting oncological diseases (comprised of both oncology and malignant hematology). Although orphan drug approvals based on NMEs are the minority of orphan drug designations, the count of approved orphan drug NMEs has increased in recent years. The characteristics of orphan drug approvals show notable differences by disease area with rare diseases and medical genetics (49%) having a relatively large fraction of orphan drug approvals with NMEs compared to the oncological diseases (32%). Similar to the use of orphan drug designation, oncological disease therapies have been the largest utilizers of AA. Many therapies targeting these diseases address unmet medical need and can leverage surrogate markers that have previously been used in similar trials. The timings of conversion of AA (confirmed or withdrawn) were assessed and found to be consistent across decades and to have some dependency upon the broad disease area (when assessed by three large groups: HIV conversions were fastest; followed by oncology; followed by all others). By the end of 2022, 98% of the first 105 (approved in 2010 or earlier) AA had been converted to confirmed or withdrawn. Conclusions Although the typical timings for AA to be confirmed or withdrawn has not changed significantly over the decades, the disease areas utilizing orphan drug designation and AA have changed significantly over time. Both programs have had increases in their use for therapies targeting oncological diseases. The re-use of surrogate markers for oncological diseases has been an advantage in a way that may not be scientifically feasible in many other disease areas that have greater differentiation across disease etiology. For non-oncological diseases, applicability of AA is, in part, dependent upon greater focus on characterization and acceptance of novel surrogate markers. |
| first_indexed | 2025-02-19T04:19:01Z |
| format | Article |
| id | mit-1721.1/157535 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2025-02-19T04:19:01Z |
| publishDate | 2024 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | mit-1721.1/1575352024-12-23T05:07:43Z Expediting treatments in the 21st century: orphan drugs and accelerated approvals Domike, Reuben Raju, G. K. Sullivan, Jamie Kennedy, Annie Massachusetts Institute of Technology. Center for Biomedical Innovation Background In response to activated patient communities’ catalyzation, two significant efforts by the FDA to expedite treatments have now been in place for multiple decades. In 1983, the United States Congress passed the Orphan Drug Act to provide financial incentives for development of drugs for rare diseases. In 1992, partly in response to the HIV epidemic, the FDA implemented Accelerated Approval (AA) to expedite access to promising new therapies to treat serious conditions with unmet medical need based on surrogate marker efficacy while additional clinical data is confirmed. The uses of these regulatory approaches over time are assessed in this study. Methods The following U.S. FDA CDER published lists were used in this analysis: 1. all orphan designations and approvals; 2. all AA and their details updated through December 31, 2022; new molecular entities (NMEs). Results Orphan drug designations and approvals have increased several-fold over the past four decades. The largest increase recently has been in therapies targeting oncological diseases (comprised of both oncology and malignant hematology). Although orphan drug approvals based on NMEs are the minority of orphan drug designations, the count of approved orphan drug NMEs has increased in recent years. The characteristics of orphan drug approvals show notable differences by disease area with rare diseases and medical genetics (49%) having a relatively large fraction of orphan drug approvals with NMEs compared to the oncological diseases (32%). Similar to the use of orphan drug designation, oncological disease therapies have been the largest utilizers of AA. Many therapies targeting these diseases address unmet medical need and can leverage surrogate markers that have previously been used in similar trials. The timings of conversion of AA (confirmed or withdrawn) were assessed and found to be consistent across decades and to have some dependency upon the broad disease area (when assessed by three large groups: HIV conversions were fastest; followed by oncology; followed by all others). By the end of 2022, 98% of the first 105 (approved in 2010 or earlier) AA had been converted to confirmed or withdrawn. Conclusions Although the typical timings for AA to be confirmed or withdrawn has not changed significantly over the decades, the disease areas utilizing orphan drug designation and AA have changed significantly over time. Both programs have had increases in their use for therapies targeting oncological diseases. The re-use of surrogate markers for oncological diseases has been an advantage in a way that may not be scientifically feasible in many other disease areas that have greater differentiation across disease etiology. For non-oncological diseases, applicability of AA is, in part, dependent upon greater focus on characterization and acceptance of novel surrogate markers. 2024-11-13T17:01:49Z 2024-11-13T17:01:49Z 2024-11-08 2024-11-10T08:19:59Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/157535 Domike, R., Raju, G.K., Sullivan, J. et al. Expediting treatments in the 21st century: orphan drugs and accelerated approvals. Orphanet J Rare Dis 19, 418 (2024). PUBLISHER_CC en https://doi.org/10.1186/s13023-024-03398-1 Orphanet Journal of Rare Diseases Creative Commons Attribution https://creativecommons.org/licenses/by/4.0/ The Author(s) application/pdf BioMed Central BioMed Central |
| spellingShingle | Domike, Reuben Raju, G. K. Sullivan, Jamie Kennedy, Annie Expediting treatments in the 21st century: orphan drugs and accelerated approvals |
| title | Expediting treatments in the 21st century: orphan drugs and accelerated approvals |
| title_full | Expediting treatments in the 21st century: orphan drugs and accelerated approvals |
| title_fullStr | Expediting treatments in the 21st century: orphan drugs and accelerated approvals |
| title_full_unstemmed | Expediting treatments in the 21st century: orphan drugs and accelerated approvals |
| title_short | Expediting treatments in the 21st century: orphan drugs and accelerated approvals |
| title_sort | expediting treatments in the 21st century orphan drugs and accelerated approvals |
| url | https://hdl.handle.net/1721.1/157535 |
| work_keys_str_mv | AT domikereuben expeditingtreatmentsinthe21stcenturyorphandrugsandacceleratedapprovals AT rajugk expeditingtreatmentsinthe21stcenturyorphandrugsandacceleratedapprovals AT sullivanjamie expeditingtreatmentsinthe21stcenturyorphandrugsandacceleratedapprovals AT kennedyannie expeditingtreatmentsinthe21stcenturyorphandrugsandacceleratedapprovals |